ArticleBioinformatics (Oxford, England)2026
M2-PRNet: multi-scale and multi-modal learning for protein-RNA binding affinity prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationPredicting protein-RNA binding affinity is crucial for understanding cellular regulation and advancing RNA-targeted drug discovery. However, this task remains challenging due to structural complexity, limited labeled data, and insufficient modeling of fine-grained interactions.
resultsWe propose M2-PRNet, a multi-scale and multi-modal framework that integrates atom-level graphs, residue-level graphs, and tri-view molecular representations to capture complementary structural information. A cross-scale contrastive learning objective is introduced to align representations across different structural resolutions of the same complex. Under a clustering-based five-fold cross-validation setting on benchmark datasets, M2-PRNet achieves state-of-the-art performance. To further assess generalization under reduced sequence homology, we construct homology-aware RNA-cold, protein-cold, and dual-cold evaluations under a stricter 40% sequence identity threshold, where M2-PRNet maintains competitive performance. To account for conformational flexibility, we evaluate the model on MD150-1ns and an extended MD75-10ns subset, demonstrating stable performance under MD-derived structural perturbations. In addition, representative case studies suggest that M2-PRNet can highlight relevant RNA-binding regions and support preliminary discrimination between strong and weak binders when plausible complex structures are available. These results demonstrate the effectiveness of integrating multi-scale and multi-modal representations with cross-scale alignment for protein-RNA affinity prediction. AVAILABILITY AND IMPLEMENTATION: The source code and datasets for M2-PRNet are freely available at https://github.com/CSUBioGroup/M2-PRNet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.